Abstract
Disease gene discovery on chromosome (chr) X is challenging owing to its unique modes of inheritance. We undertook a systematic analysis of human chrX genes. We observe a higher proportion of disorder-associated genes and an enrichment of genes involved in cognition, language, and seizures on chrX compared to autosomes. We analyze gene constraints, exon and promoter conservation, expression and paralogues, and report 127 genes sharing one or more attributes with known chrX disorder genes. Using a neural network trained to distinguish disease-associated from dispensable genes, we classify 235 genes, including 121 of the 127, as having high probability of being disease-associated. We provide evidence of an excess of variants in predicted genes in existing databases. Finally, we report damaging variants in CDK16 and TRPC5 in patients with intellectual disability or autism spectrum disorders. This study predicts large-scale gene-disease associations that could be used for prioritization of X-linked pathogenic variants.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Electrophysiological experiments were carried out at the electrophysiology core facility of ICM funded from the program "Investissements d'avenir" ANR-10-IAIHU-06. We thank Universitätsklinikum Essen, University Duisburg-Essen, the Deutsche Forschungsgemein-schaft (DFG), the Tom-Wahlig-Stiftung (TWS), the Deutsche Stiftung Neurologie (DSN), and Assistance Publique des Hôpitaux de Paris (APHP) for their financial support to the re-search studies conducted by the authors. E.L. and F.K. are associated with the FOR 2488 project (DFG, Project number 287074911). This study makes use of data generated by the DECIPHER community. A full list of centres who contributed to the generation of the data is available from https://deciphergenomics.org/about/stats and via email from contact@deciphergenomics.org. Funding for the DECIPHER project was provided by Wellcome.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Data collection sites had study protocols approved by the local Institutional Review Boards (IRB) including INSERM (RBM C12-06) and Ethik Kommission der Medizinischen Fakultät der Universität Duisburg-Essen
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript or in the supplementary data.
https://gnomad.broadinstitute.org/
https://www.ensembl.org/index.html
https://genome.ucsc.edu/cgi-bin/hgTables
